Positive Data for Lead Candidate Nu-3 Propels Lakewood-Amedex Towards Phase 2 Trial
LABT is trading near its 52-week low of $1.41 (11% below the low) on light trading volume (0.1× avg).
Summary
Lakewood-Amedex Biotherapeutics announced positive data for its lead candidate, Nu-3, specifically for infected diabetic foot ulcers. This significant development includes the completion of key formulation, delivery, and manufacturing steps, preparing the candidate for a planned Phase 2 clinical trial. For a small-cap biotech company, positive clinical data for a lead candidate advancing to Phase 2 is a highly material event that de-risks the development pipeline and could significantly increase investor confidence and valuation, especially as the stock is trading near its 52-week low. This news follows a recent agreement with a research institute (May 12) which could be related to advancing its clinical programs, but is distinct from the recent 424B4 filing (May 14) regarding share resale. Investors will now watch for the initiation and progress of the Phase 2 clinical trial for Nu-3.
At the time of this announcement, LABT was trading at $1.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21M. The 52-week trading range was $1.41 to $9.82. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.